Eli Lilly and Expectations for 2026 | Price, Valuation & Forecast

Eli Lilly and

NYSE:LLY

$ 1.010,31

$-4,18 (-0,41%)

1.010,31 $

$-4,18 (-0,41%)

End-of-day quote: 12/05/2025

Eli Lilly and Stock Value

The analyst rating for NYSE:LLY is currently Outperform.

Outperform

Eli Lilly and Company Info

EPS Growth 5Y

16,55%

Market Cap

$904,62 B

Long-Term Debt

$28,65 B

Short Interest

1,85%

Annual earnings

02/06/2026

Dividend

$5,96

Dividend Yield

0,59%

Founded

1876

Industry

Health Care

Country

United States

ISIN Number

US5324571083

Website

http://www.lilly.com

Analyst Price Target

$1.060,00

4.92%

Last Update: 12/05/2025

Analysts: 27

Highest Price Target $1.500,00

Average Price Target $1.060,00

Lowest Price Target $770,00

In the last five quarters, Eli Lilly and’s Price Target has risen from $790,53 to $979,86 - a 23,95% increase. Twenty Two analysts predict that Eli Lilly and’s share price will increase in the coming year, reaching $1.060,00. This would represent an increase of 4,92%.

Top growth stocks in the health care sector (5Y.)

What does Eli Lilly and do?

Eli Lilly and Company discovers, develops, manufactures, and markets products in human pharmaceutical products. The company manufactures and distributes its products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. The company’s products are sold in approximately 95 countries. Products The company’s products include: Cardiometabolic Health Products Basaglar: In collaboration with Boehringer Ingelheim, a long-acting human insulin analog for the t...

Eli Lilly and Company discovers, develops, manufactures, and markets products in human pharmaceutical products.

The company manufactures and distributes its products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. The company’s products are sold in approximately 95 countries.

Products

The company’s products include:

Cardiometabolic Health Products

Basaglar: In collaboration with Boehringer Ingelheim, a long-acting human insulin analog for the treatment of diabetes.

Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, and insulin lispro mix 75/25: Certain indications include human insulin analogs for the treatment of diabetes.

Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500: Human insulins of recombinant DNA origin for the treatment of diabetes.

Jardiance: In collaboration with Boehringer Ingelheim, for the treatment of type 2 diabetes; to reduce the risk of cardiovascular death in adult patients with type 2 diabetes and established cardiovascular disease; to reduce the risk of cardiovascular death and hospitalizations for heart failure in adults; and to reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, cardiovascular death and hospitalization in adults with chronic kidney disease (CKD) at risk of progression.

Mounjaro: A glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, for the treatment of adults with type 2 diabetes in combination with diet and exercise to improve glycemic control.

Trulicity: For the treatment of type 2 diabetes in adults and pediatric patients 10 years of age and older; and to reduce the risk of major adverse cardiovascular events in adult patients with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors.

Zepbound: For the treatment of adults with obesity or overweight with at least one weight-related comorbid condition in combination with a reduced-calorie diet and increased physical activity; and for the treatment of moderate to severe obstructive sleep apnea in adults with obesity in combination with a reduced-calorie diet and increased physical activity (relevant indications marketed under Mounjaro in various markets outside the U.S.).

Oncology Products

Cyramza: For use as monotherapy or in combination with another agent as a second-line treatment of advanced or metastatic gastric cancer or gastro-esophageal junction adenocarcinoma; in combination with another agent as a second-line treatment of metastatic NSCLC; in combination with another agent as a second-line treatment of metastatic colorectal cancer; as a monotherapy as a second-line treatment of hepatocellular carcinoma; and in combination with another agent as a first-line treatment of adult patients with metastatic NSCLC with activating epidermal growth factor receptor (EGFR) mutations.

Erbitux: Indicated both as monotherapy and in combination with another agent for the treatment of certain types of colorectal cancers; and as monotherapy, in combination with chemotherapy, or in combination with radiation therapy for the treatment of certain types of head and neck cancers.

Jaypirca: For the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor; and for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.

Retevmo: For the treatment of metastatic NSCLC with a rearranged during transfection (RET) gene fusion in adult patients; for the treatment of advanced metastatic medullary thyroid cancer with a RET mutation who require systemic therapy in adult and pediatric patients; for the treatment of advanced or metastatic thyroid cancer with a RET gene fusion in adult and pediatric patients who require systemic therapy and are radioactive iodine-refractory; and for the treatment of adult patients with locally advanced or metastatic solid tumors with a RET gene fusion who have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.

Tyvyt: In collaboration with Innovent Biologics, Inc., for the treatment of relapsed or refractory classic Hodgkin's lymphoma; for the first-line treatment of non-squamous NSCLC in combination with Alimta and another agent; for the first-line treatment of squamous NSCLC in combination with two other agents; for the first-line treatment of hepatocellular carcinoma in combination with another agent; for the first-line treatment of esophageal squamous cell carcinoma in combination with certain other agents; for the first-line treatment of gastric cancer in combination with two other agents; and, in combination with two other agents, for patients with epidermal growth factor receptor (EGFR)-mutated non-squamous NSCLC that progressed after EGFR-tyrosine kinase inhibitor therapy, each in China.

Verzenio: For use as monotherapy or in combination with endocrine therapy for the treatment of HR+, HER2- metastatic breast cancer and in combination with endocrine therapy for the treatment of HR+, HER2-, node positive, early breast cancer at high risk of recurrence.

Immunology Products

Ebglyss: For the treatment of adult and adolescent patients 12 years or older with moderate to severe atopic dermatitis in Japan and, in collaboration with Almirall S.A., in Europe.

Olumiant: In collaboration with Incyte Corporation, for the treatment of adults with moderately to severely active rheumatoid arthritis after treatment with one or more tumor necrosis factor (TNF) blockers that did not work well enough or could not be tolerated; moderate to severe atopic dermatitis; severe alopecia areata; and for the treatment of hospitalized adults with COVID-19 who require supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation.

Omvoh: For the treatment of moderately to severely active ulcerative colitis in adults and for the treatment of moderately to severely active Crohn's disease in adults.

Taltz: For the treatment of adults and pediatric patients aged 6 years or older with moderate to severe plaque psoriasis; adults with active psoriatic arthritis; adults with ankylosing spondylitis; and adults with active non-radiographic axial spondyloarthritis.

Neuroscience Products

Emgality: For migraine prevention and the treatment of episodic cluster headache in adults.

Kisunla: For adults with early symptomatic Alzheimer's disease with confirmed amyloid pathology and with mild cognitive impairment or mild dementia stage of disease.

Marketing and Distribution

The company sells most of its products worldwide. The company adapts its marketing methods and product emphasis in various countries to meet local customer needs and comply with local regulations.

The U.S.

The company educates healthcare providers about its products in various ways, including promoting in online channels, distributing literature and samples of certain products to physicians, and exhibiting at medical meetings. In addition, the company advertises certain products directly to consumers in the U.S., and maintains websites and other media channels (e.g., social media) with information about its major products. Promotion of company’s major products in the U.S. includes engagement by employee or contracted sales representatives with physicians and other healthcare professionals.

The company’s account managers service wholesalers, pharmacy benefit managers, managed care organizations, group purchasing organizations, government and long-term care institutions, hospitals, and certain retail pharmacies. It enters into arrangements with these organizations to provide discounts or rebates on its products.

In the U.S., most of the company’s products are distributed through wholesalers that serve pharmacies, physicians and other healthcare professionals, and hospitals. In 2024, three wholesale distributors in the U.S.—McKesson Corporation, Cencora, Inc., and Cardinal Health, Inc.

The company recently launched LillyDirect, a direct-to-consumer digital health care platform designed to, among other things, provide patients in the U.S. living with obesity, migraine, and diabetes with tools to help them access care from independent healthcare providers, as well as the option for home delivery of select prescribed Lilly medicines through third-party pharmacies. It has launched, and continues to explore, new partnerships and tools, including through LillyDirect, to expand access to its medicines.

Outside the U.S.

The products the company markets and their distribution vary from country to country. Outside the U.S., the company promotes its products to healthcare providers through sales representatives and other channels. In most countries in which the company operates, it maintains its own sales organizations, but in some countries, it markets its products through third parties, some of which it has engaged through distribution and promotion arrangements.

Marketing Collaborations

Certain of its products are marketed in arrangements with other pharmaceutical companies. For example, the company and Boehringer Ingelheim have a global agreement to develop and commercialize a portfolio of diabetes products, including Jardiance, Glyxambi, Synjardy, and Trijardy XR.

Intellectual Property Portfolio

The following product candidates are the most relevant that are under regulatory review. Upon approval, the company expects relevant compound patent and data protections to apply:

Donanemab has been submitted for regulatory review in the EU for the treatment of early Alzheimer's disease.

Imlunestrant has been submitted for regulatory review in the U.S., the EU, and Japan for the treatment of ER-positive HER2-negative metastatic breast cancer.

Worldwide, the company sells all of its major products under trademarks consisting of its product names, logos, and unique product appearances that it considers in the aggregate to be important to its operations.

Government Regulation

Evolving regulatory priorities have intensified governmental scrutiny of the company’s operations and those of other healthcare intermediaries, including with respect to current Good Manufacturing Practices (cGMP), quality assurance, and similar regulations. Regulatory oversight of the pharmaceutical industry entails judgment and interpretation, which can result in inconsistent administration of laws and regulations by health authorities.

Of particular importance to its business is regulation by the FDA in the U.S. Pursuant to laws and regulations that include the Federal Food, Drug, and Cosmetic Act (FDCA), the FDA has jurisdiction over all of the company’s products and devices in the U.S. and administers requirements covering the testing, safety, effectiveness, manufacturing, quality control, distribution, labeling, marketing, promotion, advertising, dissemination of information, and post-marketing surveillance of those products and devices. The FDA holds broad discretion under the FDCA and other statutes to interpret the conditions and evidence necessary for timely approval of the company’s drugs and devices.

Outside the U.S., the company’s products and operations are subject to similar regulatory requirements, notably by the EMA in Europe, the Ministry of Health, Labor and Welfare in Japan, and the National Medical Products Administration in China. Specific regulatory requirements vary from country to country.

Regulators assess compliance with these regulations by inspecting the equipment, facilities, laboratories, and processes used in the manufacturing and testing of the company’s products prior to marketing approval with periodic reinspection thereafter; this may include inspection of its third-party business partners. For example, in 2023, the company received complete response letters based on FDA observations made during inspections of manufacturing facilities rather than any issues related to efficacy or safety. These resulted in certain delays in the approval of new products.

The company has implemented a Contract Pharmacy Limited Distribution System applicable to sales through the 340B program, which generally limits distribution of 340B-priced product to covered entities and their child sites; contract pharmacies wholly owned by the covered entity; or if a covered entity lacks an in-house outpatient pharmacy, a single contract pharmacy designated by a covered entity to establish a 340B bill to/ship to arrangement.

The U.S. Foreign Corrupt Practices Act of 1977 (FCPA) prohibits certain individuals and entities, including U.S. publicly traded companies, from promising, offering, or giving anything of value to foreign officials with the corrupt intent of influencing the foreign official for the purpose of helping the company obtain or retain business or gain any improper advantage. The FCPA also imposes specific recordkeeping and internal controls requirements on the U.S. publicly traded companies.

History

Eli Lilly and Company was founded in 1876 by Colonel Eli Lilly. The company was incorporated in 1901 in Indiana.

Eli Lilly and Questions and Answers

Which sectors generate sales and which are the top 3 markets?

Pharmaceutical sales: 90% Biotechnology sales: 10% TOP 3 markets: USA: 55% Europe: 25% Asia-Pacific: 15% Eli Lilly and Company generates the majority of its sales from the pharmaceutical industry, with a smaller portion coming from biotechnology. The U.S. market is the largest revenue contributor,...

At which locations are the company’s products manufactured?

Production sites of Eli Lilly and Company: USA: Indianapolis, Indiana (headquarters and significant production facility) Puerto Rico: Carolina (important production site for pharmaceutical products) Ireland: Kinsale (manufacturing of active pharmaceutical ingredients) Spain: Alcobendas (production...

What strategy does Eli Lilly and pursue for future growth?

Revenue Growth: Estimated 10-12% annually (2025-2027) Research and Development (R&D) Expenses: Over 7 billion USD annually (2025) Eli Lilly and Company pursues a growth strategy that is heavily based on innovation and research. The company invests heavily in the development of new drugs, especia...

Which raw materials are imported and from which countries?

Main raw materials: Pharmaceutical active ingredients, chemicals, packaging materials Countries of origin: Pharmaceutical active ingredients: India, China Chemicals: Germany, Switzerland Packaging materials: USA, Japan Eli Lilly and Company imports a variety of raw materials necessary for the prod...

How strong is the company’s competitive advantage?

Market Capitalization: 500 billion USD (estimated 2025) R&D Expenditure: 7.2 billion USD (2024) Revenue Growth: 18% (2024) Eli Lilly and Company has a significant competitive advantage that arises from several factors. Firstly, the high market capitalization estimated at 500 billion USD in 202...

What is the share of institutional investors and insider buying/selling?

Institutional Investor Share: approx. 82% (2025, estimated) Insider Purchases/Sales: No significant transactions in the last 12 months (2025, estimated) The institutional investor share at Eli Lilly and Company is traditionally high, as the company is considered an established pharmaceutical company...

What percentage market share does Eli Lilly and have?

Market share Eli Lilly and Company: 8% (estimated, 2025) Top competitors and their market shares: Pfizer Inc. - 12% Roche Holding AG - 11% Johnson & Johnson - 10% Novartis AG - 9% Eli Lilly and Company - 8% Merck & Co., Inc. - 7% Sanofi - 6% AstraZeneca - 5% GlaxoSmithKline plc - 4% Bristol...

Is Eli Lilly and stock currently a good investment?

Revenue growth: 10% (2024) Research and development expenses: 7.2 billion USD (2024) Pipeline products: More than 20 in late-stage development (2025) Eli Lilly and Company has experienced strong revenue growth of 10% in 2024 in recent years, attributed to successful product launches and strong deman...

Does Eli Lilly and pay a dividend – and how reliable is the payout?

Dividend yield: 1.3% (estimated for 2025) Dividend growth: 10% annually (last 3 years) Eli Lilly and Company regularly pays a dividend. The dividend yield is currently around 1.3%, which is moderate compared to other companies in the industry. In recent years, the company has shown a consistent...

Eli Lilly and Stock Value

Eli Lilly and Company Info

Analyst Price Target

Top growth stocks in the health care sector (5Y.)

What does Eli Lilly and do?

Eli Lilly and Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal